WHO Prequalifies Gilead’s Lenacapavir as First Long-Acting Injectable for HIV Prevention
1 Mins read
Milestone marks first lenacapavir-based product prequalified under WHO’s new abridged pathway, enabling faster access to innovative HIV prevention options worldwide. By Bunmi…